Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL J OLIVER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1679501431
CMS profile
121491
Location
BEAVER, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,192.77

60 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,192.77 60

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL J OLIVER

NPI 1679501431 · CMS profile ID 121491

Allopathic & Osteopathic Physicians / Internal Medicine

BEAVER, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679501431?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679501431?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679501431?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1679501431?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

60 matching records · $1,192.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 60 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 60.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $13.4212/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939219487 CMS
Bayer HealthCare Pharmaceuticals Inc. $15.1412/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930133599 CMS
Novo Nordisk Inc $10.0212/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899417023 CMS
GlaxoSmithKline, LLC. $17.1712/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944922577 CMS
Astellas Pharma US Inc $14.2611/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940322747 CMS
Novo Nordisk Inc $92.7911/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898868907 CMS
GlaxoSmithKline, LLC. $19.2711/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944922581 CMS
Novo Nordisk Inc $20.6511/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899417029 CMS
Novo Nordisk Inc $23.5810/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899319859 CMS
AstraZeneca Pharmaceuticals LP $11.8010/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914914893 CMS
Bayer HealthCare Pharmaceuticals Inc. $16.0010/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929999843 CMS
GlaxoSmithKline, LLC. $15.0110/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944922583 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.3410/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887488977 CMS
Novo Nordisk Inc $124.4610/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899424961 CMS
Kowa Pharmaceuticals America, Inc. $13.0710/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 900430395 CMS
E.R. Squibb & Sons, L.L.C. $15.5909/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932924719 CMS
Novo Nordisk Inc $1.1109/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898953211 CMS
Novo Nordisk Inc $5.2109/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899092099 CMS
ABBVIE INC. $12.6109/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891285259 CMS
HeartFlow, Inc. $23.4709/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950326901 CMS
Astellas Pharma US Inc $15.6109/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940266503 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.9908/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887488979 CMS
Bayer HealthCare Pharmaceuticals Inc. $17.8208/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930046639 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.7207/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887488981 CMS
Biohaven Pharmaceutical Holding Company Ltd. $15.6407/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923690977 CMS
GlaxoSmithKline, LLC. $14.3107/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944922587 CMS
GlaxoSmithKline, LLC. $23.0407/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944922571 CMS
Novo Nordisk Inc $24.0007/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899319867 CMS
Lilly USA, LLC $21.4306/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918245261 CMS
Astellas Pharma US Inc $15.2706/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940213871 CMS
ABBVIE INC. $18.5306/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891285257 CMS
Novartis Pharmaceuticals Corporation $12.8806/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894042005 CMS
GlaxoSmithKline, LLC. $18.7305/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944922589 CMS
Amgen Inc. $18.1605/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939849325 CMS
Novo Nordisk Inc $0.4405/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898999201 CMS
Novo Nordisk Inc $22.3705/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899264539 CMS
Novo Nordisk Inc $19.3005/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899359273 CMS
GlaxoSmithKline, LLC. $15.0005/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944922573 CMS
ABBVIE INC. $24.1504/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891285255 CMS
Novartis Pharmaceuticals Corporation $14.1804/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894042001 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.8104/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887488983 CMS
Amarin Pharma Inc. $12.7404/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913920113 CMS
Lilly USA, LLC $20.0004/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918200703 CMS
Novo Nordisk Inc $75.6004/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899359279 CMS
Merck Sharp & Dohme LLC $16.7504/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944348783 CMS
E.R. Squibb & Sons, L.L.C. $13.1603/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932924657 CMS
Novartis Pharmaceuticals Corporation $15.5003/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894041997 CMS
GlaxoSmithKline, LLC. $13.0903/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944922579 CMS
Novo Nordisk Inc $9.7403/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899224195 CMS
Dynavax Technologies Corporation $17.3303/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896840543 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,982.16 111
PY2020 $387.82 28
PY2021 $1,408.56 66
PY2022 $1,192.77 60
PY2023 $1,343.06 63
PY2024 $1,223.14 62
PY2025 $1,203.19 61

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,083,959.47 12
PY2024 Recipient $43,914.50 5
PY2024 Principal investigator $1,015,962.54 15
PY2023 Recipient $195.00 1
PY2023 Principal investigator $828,848.21 14
PY2022 Recipient $34,661.00 4
PY2022 Principal investigator $514,412.47 14
PY2021 Principal investigator $507,716.92 33
PY2020 Recipient $5,278.97 8
PY2020 Principal investigator $291,944.00 17
PY2019 Recipient $10,899.97 2
PY2019 Principal investigator $442,530.95 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $1,019.00 11/16/2022 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 917848519
Principal investigator 1 Eli Lilly and Company $104,667.00 10/25/2022 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS No dispute reported 06/30/2026 917848509
Recipient Eli Lilly and Company $19,665.00 07/13/2022 Covered Recipient Physician A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS No dispute reported 06/30/2026 917812839
Principal investigator 1 Eli Lilly and Company $24,023.00 06/29/2022 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS No dispute reported 06/30/2026 917842779
Principal investigator 1 Eli Lilly and Company $150,649.00 06/28/2022 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) No dispute reported 06/30/2026 917845565
Recipient Eli Lilly and Company $779.00 06/08/2022 Covered Recipient Physician A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 917813027
Principal investigator 1 Eli Lilly and Company $2,088.00 05/26/2022 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) No dispute reported 06/30/2026 917845557
Recipient Eli Lilly and Company $307.00 05/09/2022 Covered Recipient Physician A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) No dispute reported 06/30/2026 917814319
Recipient Eli Lilly and Company $13,910.00 04/08/2022 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) No dispute reported 06/30/2026 917812835
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,559.47 03/28/2022 Non-covered Recipient Entity
Hvmg Valley Internal Medicine
Phase II study of BI456906 in Patients with T2DM O No dispute reported 06/30/2026 949201495
Principal investigator 1 Eli Lilly and Company $233.00 02/08/2022 Non-covered Recipient Entity
LCGK RSRCH
A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) No dispute reported 06/30/2026 917824103
Principal investigator 1 Eli Lilly and Company $533.00 02/08/2022 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 917844689
Principal investigator 1 Eli Lilly and Company $48.00 01/31/2022 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 917845741
Principal investigator 1 Eli Lilly and Company $16,519.00 01/27/2022 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) No dispute reported 06/30/2026 917842773
Principal investigator 1 Eli Lilly and Company $9,215.00 01/26/2022 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 917844697
Principal investigator 1 Eli Lilly and Company $73,133.00 01/11/2022 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 917845375
Principal investigator 1 Eli Lilly and Company $84,825.00 01/11/2022 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 917848505
Principal investigator 1 Eli Lilly and Company $35,901.00 01/04/2022 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) No dispute reported 06/30/2026 917848497